Agilent completed its acquisition of Biocare Medical, a deal originally announced in March and valued at $950 million. The move expands Agilent’s pathology offerings with Biocare’s immunohistochemistry, in situ hybridization, and fluorescence in situ hybridization assay portfolio, including more than 300 specialized antibodies. Biocare will be folded into Agilent’s Life Sciences and Diagnostics Markets Group, strengthening the company’s position in workflows tied to translational research and clinical pathology. For diagnostics and laboratory equipment providers, the transaction signals continued consolidation in pathology reagent ecosystems—an area closely connected to companion diagnostics, biomarker development, and oncology testing demand.